folowing amendments reflect that interview and respond to the formal rejections in the prior Office Action.

IN THE CLAIMS

The current status of every claim 1-44 is as follows:

1-31 (Cancelled as non-elected in this divisional application.)

32. (Currently Amended) A vasodilator [~~Vasodilator~~] delivery system [~~systems~~] specially adapted to deliver about about 0.02 to 20 milligrams per day dosage of vasodilators and marked with the appropriate DRG and/or ICD disease codes and/or instructions for titrating or tapering their use, to facilitate their proper application for treatment of diseases involving vasospasm.

E1

33.(Previously Added) A delivery system according to Claim 32 adapted for transdermal delivery.

34. (Previously Amended) A delivery system according to Claim 38 adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.

35. (Previously Amended) A delivery system according to Claim 32 adapted for delivery of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, isradipine, hydrazine, nifedipine, and/or other medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

36. (Currently Amended) A system ~~[method]~~ according to Claim 32 wherein the disease is selected from the group consisting of fibromyalgia, gastric disorders and other systemic disorders, psychosis, other psychiatric disease, attention deficit disorder and systemic disorders, comprising vasospasm as a component.

37. (Previously Amended) A system according to Claim 32 wherein the disease is selected from the group consisting of systemic disorders comprising vasospasm as a component.

38. (Previously Amended) A titration system for diagnosing and treating a disease caused at least partially by insufficient cerebral perfusion, comprising in combination: a flow measuring device to test for vasospasm, a dosage device which administers a vasospasm-reducing dosage of a medicine selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which reduce pulmonary capillary wedge pressure, and said dosage device being adjustable over time to titrate said dosage in response to said testing to minimize occurrence and severity of said vasospasm.

39. (Previously Added) A system according to Claim 38 wherein the flow measuring device comprises transcranial doppler measuring means.

40. (Previously Added) A system according to Claim 38 wherein the dosage device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment, cream, inhaler, spray and other forms, Nitroglycerin equivalents and substitutes, comprising p.o. clonidine, isradipine,

hydrazine, nifedipine, and/or other medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

41. (Previously Added) A system according to Claim 38 wherein the flow measuring device comprises transcranial doppler measuring means and the dosage device comprises transdermal,inhaler, spray and other forms of vasodilator selected from the group consisting of Nitroglycerin, Nitroglycerin equivalents and substitutes, p.o. clonidine, isradipine, hydrazine, nifedipine, and/or other medicines selected from the empirical group of medications which have the common characteristic of causing smooth muscle relaxation and/or which systemically reduce pulmonary capillary wedge pressure, and combinations of the foregoing.

42. (Previously Added) A system according to Claim 41 wherein the delivery device comprises means for delivering a vasodilator selected from the group comprising Nitroglycerin in pill, patch, ointment or cream form.

43. (Previously Added) A system according to Claim 46 wherein the delivery system is adapted for transdermal delivery.

44. (Previously Added) A system according to Claim 38 wherein the delivery system is adapted for the adjusting of the dosage device over time within the range of about 0.02 to 20 milligrams per day (Nitroglycerin equivalent) of vasodilator.